Q1 earnings beat lifts shares; 2026 guidance narrows as Keytruda grows, Gardasil declines and R&D jumps on deals.

Merck MRK reported an adjusted loss of $1.28 per share for the first quarter of 2026, which was narrower than the Zacks ...

Global pharmaceutical company Merck (NYSE:MRK) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with ...

Merck’s widely used immunotherapy, Keytruda, drove the company’s topline growth during the quarter, accounting for nearly ...

Merck (MRK) delivered earnings and revenue surprises of +15.47% and +2.44%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Performing Dow Stocks So Far in 2026.

Merck is scheduled to report first-quarter earnings on April 30, during market hours, with analysts expecting a strong ...

Merck (NYSE: MRK) recently announced its first-quarter results, exceeding Wall Street’s expectations for both earnings and revenue. The company reported revenues of $15.53 billion and adjusted ...

Sandisk, Marvell, and AMD. Please visit Jim Cramer’s 12 Stock Calls: GE Vernova, Arm, and Vertiv, if you’d like to see the ...

Merck (MRK) stock climbed 3% after FDA granted priority review for KEYTRUDA bladder cancer treatment combination, with ...

Merck (MRK)’s stock surged by 41% in the last six months, driven not only by a modest revenue increase but also by a significant profit jump and heightened investor confidence. The factors behind this ...